Deciphering fibroblast-induced drug resistance in non-small cell lung carcinoma through patient-derived organoids in agarose microwells.
Lab Chip.
2024 Mar 26;24(7):2025-2038. doi: 10.1039/d3lc01044a. PubMed PMID:
38410967; PubMed Central PMCID:
PMC11209828.
In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1 -mutant lung cancer.
bioRxiv.
2023 Apr 20;. doi: 10.1101/2023.04.18.537350. PubMed PMID:
37131623; PubMed Central PMCID:
PMC10153147.
Myo1e overexpression in lung adenocarcinoma is associated with increased risk of mortality.
Sci Rep.
2023 Mar 13;13(1):4107. doi: 10.1038/s41598-023-30765-y. PubMed PMID:
36914720; PubMed Central PMCID:
PMC10011530.
Non-small cell lung carcinoma spheroid models in agarose microwells for drug response studies.
Lab Chip.
2022 Jun 14;22(12):2364-2375. doi: 10.1039/d2lc00244b. PubMed PMID:
35551303; PubMed Central PMCID:
PMC10319040.
Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.
Cancer Res.
2020 Oct 1;80(19):4224-4232. doi: 10.1158/0008-5472.CAN-20-0141. Epub 2020 Aug 3. PubMed PMID:
32747363; PubMed Central PMCID:
PMC7541638.
CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC.
Cancer Res.
2019 Sep 1;79(17):4439-4452. doi: 10.1158/0008-5472.CAN-19-0024. Epub 2019 Jul 4. PubMed PMID:
31273063; PubMed Central PMCID:
PMC6746175.
PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.
Genome Med.
2018 May 31;10(1):41. doi: 10.1186/s13073-018-0546-1. PubMed PMID:
29848362; PubMed Central PMCID:
PMC5977747.
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.
Cancer Discov.
2018 Jan;8(1):59-73. doi: 10.1158/2159-8290.CD-17-0461. Epub 2017 Oct 20. PubMed PMID:
29054992; PubMed Central PMCID:
PMC5819998.
Inhibition of SIRT2 suppresses hepatic fibrosis.
Am J Physiol Gastrointest Liver Physiol.
2016 Jun 1;310(11):G1155-68. doi: 10.1152/ajpgi.00271.2015. Epub 2016 Apr 28. PubMed PMID:
27125275; PubMed Central PMCID:
PMC4935480.
Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Response.
Cancer Res.
2016 May 15;76(10):3111. doi: 10.1158/0008-5472.CAN-16-0610. Epub 2016 May 2. PubMed PMID:
27197235.
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Cancer Res.
2016 Mar 1;76(5):999-1008. doi: 10.1158/0008-5472.CAN-15-1439. Epub 2016 Feb 1. PubMed PMID:
26833127; PubMed Central PMCID:
PMC4775354.
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Cancer Res.
2015 Oct 15;75(20):4372-83. doi: 10.1158/0008-5472.CAN-15-0377. Epub 2015 Aug 17. PubMed PMID:
26282169; PubMed Central PMCID:
PMC4548796.
Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.
Cancer Cell.
2014 Dec 8;26(6):909-922. doi: 10.1016/j.ccell.2014.10.019. PubMed PMID:
25490451; PubMed Central PMCID:
PMC4261156.
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Cancer Discov.
2013 Dec;3(12):1355-63. doi: 10.1158/2159-8290.CD-13-0310. Epub 2013 Sep 27. PubMed PMID:
24078774; PubMed Central PMCID:
PMC3864135.
Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Clin Cancer Res.
2013 Nov 15;19(22):6183-92. doi: 10.1158/1078-0432.CCR-12-3904. Epub 2013 Sep 17. PubMed PMID:
24045185; PubMed Central PMCID:
PMC3838895.
HIF1α and HIF2α independently activate SRC to promote melanoma metastases.
J Clin Invest.
2013 May;123(5):2078-93. doi: 10.1172/JCI66715. Epub 2013 Apr 8. PubMed PMID:
23563312; PubMed Central PMCID:
PMC3635738.
Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.
Cancer Res.
2013 Jan 15;73(2):834-43. doi: 10.1158/0008-5472.CAN-12-2066. Epub 2012 Nov 19. PubMed PMID:
23172312; PubMed Central PMCID:
PMC3994895.
Suppression of neointimal hyperplasia following angioplasty-induced vascular injury in pigs infected with swinepox virus.
Open Virol J.
2012;6:91-6. doi: 10.2174/1874357901206010091. Epub 2012 Oct 15. PubMed PMID:
23136622; PubMed Central PMCID:
PMC3486964.
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Cancer Discov.
2012 Oct;2(10):934-47. doi: 10.1158/2159-8290.CD-12-0103. Epub 2012 Sep 7. PubMed PMID:
22961667; PubMed Central PMCID:
PMC3477553.
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Clin Cancer Res.
2012 Sep 15;18(18):4973-85. doi: 10.1158/1078-0432.CCR-11-2967. Epub 2012 Jul 17. PubMed PMID:
22806877; PubMed Central PMCID:
PMC3477583.
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.
Cancer Res.
2012 Jul 1;72(13):3302-11. doi: 10.1158/0008-5472.CAN-11-3720. Epub 2012 May 2. PubMed PMID:
22552292; PubMed Central PMCID:
PMC3389159.
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.
Cancer Cell.
2012 Jun 12;21(6):751-64. doi: 10.1016/j.ccr.2012.03.048. PubMed PMID:
22698401; PubMed Central PMCID:
PMC3660964.
Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer.
Proc Natl Acad Sci U S A.
2012 May 29;109(22):8699-704. doi: 10.1073/pnas.1017909109. Epub 2012 May 15. PubMed PMID:
22589302; PubMed Central PMCID:
PMC3365195.
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
Nature.
2012 Mar 18;483(7391):613-7. doi: 10.1038/nature10937. PubMed PMID:
22425996; PubMed Central PMCID:
PMC3385933.
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
Cancer Res.
2011 Sep 15;71(18):6051-60. doi: 10.1158/0008-5472.CAN-11-1340. Epub 2011 Jul 26. PubMed PMID:
21791641; PubMed Central PMCID:
PMC3278914.
Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
Mol Cancer Ther.
2011 May;10(5):806-16. doi: 10.1158/1535-7163.MCT-10-1050. Epub 2011 Mar 18. PubMed PMID:
21421804; PubMed Central PMCID:
PMC3092019.
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
Cancer Res.
2010 Dec 1;70(23):9827-36. doi: 10.1158/0008-5472.CAN-10-1671. Epub 2010 Oct 15. PubMed PMID:
20952506; PubMed Central PMCID:
PMC3043107.
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.
Cancer Cell.
2010 Jun 15;17(6):547-59. doi: 10.1016/j.ccr.2010.04.026. PubMed PMID:
20541700; PubMed Central PMCID:
PMC2901842.
Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.
Blood.
2010 Apr 8;115(14):2901-9. doi: 10.1182/blood-2009-03-209544. Epub 2010 Feb 16. PubMed PMID:
20160166; PubMed Central PMCID:
PMC2854433.
TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.
Oncogene.
2010 Mar 18;29(11):1588-97. doi: 10.1038/onc.2009.452. Epub 2009 Dec 7. PubMed PMID:
19966866; PubMed Central PMCID:
PMC2841700.
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
J Clin Invest.
2009 Jun;119(6):1727-40. doi: 10.1172/JCI37127. Epub 2009 May 18. PubMed PMID:
19451690; PubMed Central PMCID:
PMC2689116.
Somatic LKB1 mutations promote cervical cancer progression.
PLoS One.
2009;4(4):e5137. doi: 10.1371/journal.pone.0005137. Epub 2009 Apr 2. PubMed PMID:
19340305; PubMed Central PMCID:
PMC2660434.
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
Proc Natl Acad Sci U S A.
2009 Jan 13;106(2):474-9. doi: 10.1073/pnas.0808930106. Epub 2009 Jan 2. PubMed PMID:
19122144; PubMed Central PMCID:
PMC2626727.
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
PLoS One.
2008;3(12):e3908. doi: 10.1371/journal.pone.0003908. Epub 2008 Dec 12. PubMed PMID:
19079597; PubMed Central PMCID:
PMC2592703.
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
Oncogene.
2008 Aug 7;27(34):4702-11. doi: 10.1038/onc.2008.109. Epub 2008 Apr 14. PubMed PMID:
18408761; PubMed Central PMCID:
PMC2748240.
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
Cancer Res.
2008 Jul 15;68(14):5827-38. doi: 10.1158/0008-5472.CAN-07-5428. PubMed PMID:
18632637; PubMed Central PMCID:
PMC3272303.
Heat shock protein 90 inhibition in lung cancer.
J Thorac Oncol.
2008 Jun;3(6 Suppl 2):S152-9. doi: 10.1097/JTO.0b013e318174ea3a. Review. PubMed PMID:
18520302; PubMed Central PMCID:
PMC4475350.
NF-kappaB controls growth of glioblastomas/astrocytomas.
Mol Cell Biochem.
2008 Jan;307(1-2):141-7. doi: 10.1007/s11010-007-9593-4. Epub 2007 Sep 9. PubMed PMID:
17828582.
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Cancer Res.
2007 Dec 15;67(24):11924-32. doi: 10.1158/0008-5472.CAN-07-1885. PubMed PMID:
18089823.
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Cancer Res.
2007 Dec 15;67(24):11867-75. doi: 10.1158/0008-5472.CAN-07-1961. PubMed PMID:
18089817.
LKB1 modulates lung cancer differentiation and metastasis.
Nature.
2007 Aug 16;448(7155):807-10. doi: 10.1038/nature06030. Epub 2007 Aug 5. PubMed PMID:
17676035.
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
Oncogene.
2007 Jul 26;26(34):5023-7. doi: 10.1038/sj.onc.1210292. Epub 2007 Feb 19. PubMed PMID:
17311002.
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.
Cancer Cell.
2007 Jul;12(1):81-93. doi: 10.1016/j.ccr.2007.06.005. PubMed PMID:
17613438.
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.
Cancer Biol Ther.
2007 May;6(5):661-7. doi: 10.4161/cbt.6.5.4003. Epub 2007 Feb 13. PubMed PMID:
17495523.
Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.
J Clin Invest.
2007 Feb;117(2):346-52. doi: 10.1172/JCI30446. Epub 2007 Jan 25. PubMed PMID:
17256054; PubMed Central PMCID:
PMC1770949.
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Cancer Res.
2006 Dec 1;66(23):11389-98. doi: 10.1158/0008-5472.CAN-06-2318. PubMed PMID:
17145885.
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Cancer Res.
2006 Jul 1;66(13):6487-91. doi: 10.1158/0008-5472.CAN-06-0971. PubMed PMID:
16818618.
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Cancer Cell.
2006 Jun;9(6):485-95. doi: 10.1016/j.ccr.2006.04.022. Epub 2006 May 25. PubMed PMID:
16730237.
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Proc Natl Acad Sci U S A.
2006 May 16;103(20):7817-22. doi: 10.1073/pnas.0510284103. Epub 2006 May 3. PubMed PMID:
16672372; PubMed Central PMCID:
PMC1456806.
Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
Cancer Res.
2005 Jul 15;65(14):6401-8. doi: 10.1158/0008-5472.CAN-05-0933. PubMed PMID:
16024644.
What would you like to do?